^
    1m
    PIVOT-006: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT (clinicaltrials.gov)
    P3, N=367, Active, not recruiting, CG Oncology, Inc. | Trial primary completion date: Jun 2026 --> Nov 2026
    Trial primary completion date
    |
    cretostimogene grenadenorepvec (CG0070)
    1m
    Rescue of Suprasellar Metastasis of EGFR-mutant NSCLC by Daily Osimertinib Re-escalation With Filgrastim Support. (PubMed, In Vivo)
    This case suggests that dose reduction can weaken the effect of osimertinib on the CNS and that maintaining dose intensity using granulocyte colony-stimulating factor support is a viable and effective strategy for controlling CNS lesions in eloquent areas when local therapy is contraindicated.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Neupogen (filgrastim)
    1m
    Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma (clinicaltrials.gov)
    P2, N=174, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Jan 2028 --> Feb 2027
    Trial completion date
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • mesna • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    2ms
    Neupogen/MSCs conditioned media inhibit HEp-2 laryngeal cancer cells proliferation by down regulating miRNA 21expression and ROS production. (PubMed, Mol Biol Rep)
    Neupogen and MSCs-conditioned media are effective in suppressing the proliferation of Hep2 cells by targeting various components of the ROS-cytokine- STAT3-miRNA-21 signaling axis. Their combined therapy has shown potent anticancer effects, which are promising to be used in multi-targeted cancer treatment.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MIR21 (MicroRNA 21)
    |
    Neupogen (filgrastim)
    2ms
    JX594-REN026: A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=95, Completed, SillaJen, Inc. | Active, not recruiting --> Completed | Phase classification: P1b/2a --> P1/2
    Trial completion • Phase classification
    |
    Libtayo (cemiplimab-rwlc) • Pexa-Vec (pexastimogene devacirepvec)
    2ms
    NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)
    P2, N=42, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2026 --> Mar 2026
    Trial completion • Trial completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane • Leukine (sargramostim)
    2ms
    Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, St. Jude Children's Research Hospital
    New P2 trial
    |
    cyclophosphamide • Campath (alemtuzumab) • sirolimus • hydroxyurea • thiotepa • Neupogen (filgrastim) • Orencia (abatacept)
    2ms
    A novel oncolytic herpes simplex virus type 2 induces polarization of tumor-associated macrophages and remodels the immune microenvironment in glioblastoma. (PubMed, Cancer Immunol Immunother)
    OH2 exerts antitumor activity in GBM through direct oncolysis and immune microenvironment modulation, highlighting its potential as an immunotherapeutic strategy.
    Journal
    |
    STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    BS001
    3ms
    GPAD-3: Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease (clinicaltrials.gov)
    P2, N=151, Completed, Emory University | Recruiting --> Completed | Trial completion date: Dec 2025 --> Jul 2025 | Trial primary completion date: Dec 2025 --> Jul 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Leukine (sargramostim)
    3ms
    Oncolytic vaccinia virus JX-594 shows subtype-specific activity and candidate biomarkers in gastric cancer cell lines. (PubMed, Sci Rep)
    Notably, JX-594 activity was not correlated with TK1 or EGFR expression, suggesting additional determinants of viral susceptibility in GC. These findings provide preclinical evidence that molecular heterogeneity influences the response of GC to oncolytic virotherapy and support further investigation of JX-594 as a potential therapeutic strategy for gastric cancer.
    Preclinical • Journal • MSi-H Biomarker
    |
    EGFR (Epidermal growth factor receptor) • MSI (Microsatellite instability) • IL1A (Interleukin 1, alpha) • IL4I1 (Interleukin 4 Induced 1) • MX1 (MX Dynamin Like GTPase 1)
    |
    MSI-H/dMMR • EGFR expression
    |
    Pexa-Vec (pexastimogene devacirepvec)
    3ms
    Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer. (PubMed, J Surg Oncol)
    Intratumoral IT injection is a viable treatment option that may minimize systemic exposure while maintaining therapeutic efficacy. Breast surgeons can play a role in intratumoral IT in BC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Imlygic (talimogene laherparepvec) • Voyager-V1
    3ms
    Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, St. Jude Children's Research Hospital
    New P1 trial
    |
    Neupogen (filgrastim) • plerixafor